Mark Epstein

Mark E. Epstein is a Managing Partner at MTS Health Partners, L.P. ("MTS Partners"), a boutique investment bank founded in 1999 that provides strategic and financial advice to the healthcare industry. He joined MTS as a Partner in January 2008, where he was primarily responsible for building out the firm's life-sciences and financing practices, and was elevated to Managing Partner in 2018. Across his career he has completed more than 200 private financings for clients, raising over $10 billion in private capital, using instruments including PIPEs, crossover rounds, and acquisition financings.

Before MTS, Epstein was a Managing Director and co-head of Banc of America Securities' Private Equity Placements Group. Earlier in his career he served as a Vice President at Merrill Lynch & Co., where he co-headed direct private equity placements, and he held roles at Prime Charter and at Dean Witter Reynolds, where he began his career in 1992. Over roughly 25+ years of investment-banking experience, he has focused on privately negotiated financing transactions within the healthcare sector.

Epstein earned a B.S. from The Wharton School of Business at the University of Pennsylvania, graduating magna cum laude. Through his career he has developed long-standing relationships across venture capital funds, hedge funds, and special-situations funds focused on biotechnology and healthcare — the buy-side network he taps to place his clients' financings.

It is worth noting that MTS Partners is an advisory and capital-placement firm; a related but separately branded private-equity arm, MTS Health Investors, historically operated as the direct-investing side of the MTS franchise. Epstein sits on the investment-banking/advisory side, so he is best understood as a healthcare capital-markets banker rather than a personal angel or seed-stage venture investor.

*(No publicly stated personal "investment thesis" as an angel investor was found in primary sources — consistent with his role as a banker/placement agent rather than a fund principal.)*

• Sector: Deep, career-long specialization in healthcare and life sciences — biotechnology, therapeutics, and healthcare services.
• What he does: Structures and places privately negotiated financings (PIPEs, crossover rounds, growth capital, acquisition financings) and advises on strategic/M&A transactions, rather than deploying his own capital at the seed stage.
• Buy-side network: Leverages long-standing relationships with venture, hedge, and special-situations funds focused on biotech/healthcare to match issuers with institutional capital.
• Firm track record framing his approach: MTS positions itself as a boutique that has executed 281+ transactions representing over $78bn of value for healthcare clients since 1999; Epstein personally accounts for 200+ private financings totaling $10bn+.

No verifiable list of personal angel/venture portfolio companies for Mark Epstein was found in primary or reputable sources. His deal activity is as a placement agent and M&A advisor at MTS Health Partners across healthcare and life-sciences financings, not as a named equity investor in specific startups. Specific transactions could not be attributed to him with sufficient sourcing, and are therefore omitted rather than guessed.